The study has been conducted by the Microdose’s collaborators at the University of Pittsburgh with atropine sulfate delivered from the MicroDose proprietary dry powder inhaler (DPI).
The Phase I trial compared multiple inhalations of an atropine dry powder with one dose of a commercially marketed atropine intramuscular (IM) injection.
MicroDose Product Commercialization Group senior director Robert Cook said follow-up trials will further demonstrate their ability to achieve high atropine bioavailability from the MicroDose inhaler (85%, relative to IM atropine) to attain both local and systemic signs of atropinization.